PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-10.82%
G&A reduction while Biotechnology median is 0.00%. Seth Klarman would investigate efficiency gains.
No Data
No Data available this quarter, please select a different quarter.
-166.83%
Other expenses reduction while Biotechnology median is 0.00%. Seth Klarman would investigate advantages.
-35.81%
Operating expenses reduction while Biotechnology median is 1.02%. Seth Klarman would investigate advantages.
-35.81%
Total costs reduction while Biotechnology median is 0.00%. Seth Klarman would investigate advantages.
1.74%
Interest expense change of 1.74% versus flat Biotechnology costs. Walter Schloss would verify control.
-142558.33%
D&A reduction while Biotechnology median is 0.00%. Seth Klarman would investigate efficiency.
-488.78%
EBITDA decline while Biotechnology median is 0.00%. Seth Klarman would investigate causes.
No Data
No Data available this quarter, please select a different quarter.
36.41%
Income change of 36.41% versus flat Biotechnology. Walter Schloss would verify quality.
No Data
No Data available this quarter, please select a different quarter.
2042.35%
Other expenses change of 2042.35% versus flat Biotechnology. Walter Schloss would verify control.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
4.49%
Tax expense change of 4.49% versus flat Biotechnology. Walter Schloss would verify strategy.
439.57%
Income change of 439.57% versus flat Biotechnology. Walter Schloss would verify quality.
No Data
No Data available this quarter, please select a different quarter.
440.81%
EPS growth exceeding 1.5x Biotechnology median of 4.32%. Joel Greenblatt would investigate advantages.
440.81%
Diluted EPS growth exceeding 1.5x Biotechnology median of 3.55%. Joel Greenblatt would investigate advantages.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.